We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has C4 Therapeutics, Inc. (CCCC - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
C4 Therapeutics, Inc. is one of 886 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. C4 Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CCCC's full-year earnings has moved 29.1% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, CCCC has moved about 90.1% on a year-to-date basis. At the same time, Medical stocks have lost an average of 6.4%. This means that C4 Therapeutics, Inc. is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Contineum Therapeutics, Inc. (CTNM - Free Report) . The stock has returned 24.3% year-to-date.
Over the past three months, Contineum Therapeutics, Inc.'s consensus EPS estimate for the current year has increased 8.4%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, C4 Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 430 individual stocks and currently sits at #144 in the Zacks Industry Rank. Stocks in this group have gained about 0.7% so far this year, so CCCC is performing better this group in terms of year-to-date returns. Contineum Therapeutics, Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on C4 Therapeutics, Inc. and Contineum Therapeutics, Inc. as they attempt to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has C4 Therapeutics, Inc. (CCCC - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
C4 Therapeutics, Inc. is one of 886 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. C4 Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CCCC's full-year earnings has moved 29.1% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, CCCC has moved about 90.1% on a year-to-date basis. At the same time, Medical stocks have lost an average of 6.4%. This means that C4 Therapeutics, Inc. is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Contineum Therapeutics, Inc. (CTNM - Free Report) . The stock has returned 24.3% year-to-date.
Over the past three months, Contineum Therapeutics, Inc.'s consensus EPS estimate for the current year has increased 8.4%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, C4 Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 430 individual stocks and currently sits at #144 in the Zacks Industry Rank. Stocks in this group have gained about 0.7% so far this year, so CCCC is performing better this group in terms of year-to-date returns. Contineum Therapeutics, Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on C4 Therapeutics, Inc. and Contineum Therapeutics, Inc. as they attempt to continue their solid performance.